BioMarin stock surged Friday after winning Food and Drug Administration approval for its dwarfism treatment in children as young as 5.
X The drug called Voxzogo treats achondroplasia, a form of short-limbed dwarfism.With the approval, patients in the U.S.can begin treatment as young as age 5.The BioMarin Pharmaceutical ( BMRN ) drug encourages growth before a patient’s growth plates close.
Piper Sandler analyst Christopher Raymond noted the FDA approval “is right down the fairway.” In Europe, the drug is allowed in children beginning at age 2.
“Most importantly, with this approval, BioMarin’s next growth inflection is finally unlocked,” he said in a report to clients.”We model Voxzogo revenues of $165 million, $449 million, $558 million and $630 million in fiscal years 2022-25.”
IBD Newsletters Get exclusive IBD analysis and actionable news daily.
SIGN UP NOW! IBD Newsletters Get exclusive IBD analysis and actionable news daily.
Financial Advisor Update How To Invest Market Prep Tech Report Please enter a valid email address Please select a newsletter GO Get these newsletters delivered to your inbox & more info about our products & services.Privacy Policy & Terms of Use
x Thank You! You will now receive IBD Newsletters ALL DONE! Something Went Wrong! Please contact customer service CLOSE In midday trading on today’s stock market , BioMarin stock popped 8.2% near 89.70.The news sent BioMarin stock to its highest point since January.
BioMarin Stock Pops On FDA Approval In children with achondroplasia, the gene that controls bone tissue growth contains a mutation.It’s a spontaneous mutation in 80% of patients.
Others have an inherited mutation .Voxzogo bypasses that gene to promote endochondral bone growth.
This is also the first treatment option for children with achondroplasia, BioMarin Chief Executive Jacques Bienaime said in a written statement.
“Voxzogo is a medical first that is rooted in BioMarin’s focus on molecular genetics and targets the underlying cause of the condition,” he said.
“More than a decade of scientific research underpins the medical advance that Voxzogo represents.”
Piper Sandler’s Raymond kept his overweight rating and 121 price target on BioMarin stock after the approval.
Why This Launch Could Be Big SVB Leerink analyst Joseph Schwartz expects the Voxzogo launch to be among BioMarin’s biggest.He raised his price on BioMarin stock to 112 from 108 days ahead of the approval.
Voxzogo aims to increase annualized growth velocity — how much and quickly a child grows over the course of a year.Schwartz acknowledges achondroplasia is a complex disorder.In testing, Voxzogo showed trends toward improving body proportionality.
But the results weren’t statistically significant.
“However, according to our survey, physicians believe that annualized growth velocity improvement is meaningful and likely to translate into additional benefits, including quality of life improvements,” he said in a note.
Schwartz’s survey of physicians suggests Voxzogo could capture about 25% of the market at its peak.He has an outperform rating on BioMarin stock.
Follow Allison Gatlin on Twitter at @IBD_AGatlin .
YOU MAY ALSO LIKE:
Pfizer, Moderna Stocks Jump After FDA Allows Covid Boosters For All Adults
Cassava Sciences In Hot Water Again As Shorts Claim ‘Extreme’ Data Manipulation
Get Timely Buy & Sell Alerts With IBD Leaderboard
Learn How To Time The Market With IBD’s ETF Market Strategy
Want More IBD Insights? Subscribe To Our Investing Podcast!
Related news Uniqure Hits Pay Dirt In Gene Therapy And The Biotech Stock Bounds Higher 11/19/2020 Shares of QURE stock bounded higher Thursday after Uniqure reported promising results for its hemophilia B gene therapy.The company…
11/19/2020 Shares of QURE stock bounded higher Thursday after Uniqure reported…
BioMarin Pharmaceutical Hikes Earnings Guidance; Sales Beat Views Good News For BioMarin Pharmaceutical Comes With Caveat For Wary Investors Ultragenyx Pharmaceutical Finds Rare Success In Attacking Ultrarare Diseases Horizon Therapeutics, IBD Stock Of The Day, Rides Rare-Disease Drug To Buy Points How Do Tech Stocks Present A Follow-On Buy Point? ServiceNow Offers Clues Gilead Sciences Disappointed By FDA Arthritis Drug Decision; GILD Stock Falls BioMarin Handed Setback By FDA On Hemophilia Drug; BMRN Stock Plunges PayPal Stock, Futu Among 10 New Names On IBD’s Watchlists Today’s Spotlight Best Online Broker Survey How would you rate your online broker? Tell us and you could win one of ten $50 prizes! IBD Digital: Save Over $60 Free Access Week is over, but now you can get 8 more weeks of IBD Digital for only $8! Growth Stories: IBD’s New Podcast! Check out IBD’s new podcast! We’re examining the innovations behind winning stocks.More News Supply-chain woes are roiling holiday shipments.
Expect to pay a lot more for gifts this year.(© Dave Cutler)
Supply Chain Issues: Stock Winners And Losers, And What You’ll Pay This Holiday Season Tesla Stock Faces A $213 Billion Challenge Crypto-Currency is Here to Stay Promoted Content By Ault Media Group, Inc
TRADING CENTER INVESTING RESOURCES Take a Trial Today Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20!
IBD Videos Get market updates, educational videos, webinars, and stock analysis.
Get Started Learn how you can make more money with IBD’s investing tools, top-performing stock lists, and educational content..
